piRNAs in Gastric Cancer: A New Approach Towards Translational Research.

piRNAs in Gastric Cancer: A New Approach Towards Translational Research.

Publication date: Mar 19, 2020

Gastric cancer is currently the third leading cause of cancer-related deaths worldwide, usually diagnosed at late stages. The development of new biomarkers to improve its prevention and patient management is critical for disease control. piRNAs are small regulatory RNAs important for gene silencing mechanisms, mainly associated with the silencing of transposable elements. piRNA pathways may also be involved in gene regulation and the deregulation of piRNAs may be an important factor in carcinogenic processes. Thus, several studies suggest piRNAs as potential cancer biomarkers. Translational studies suggest that piRNAs may regulate key genes and pathways associated with gastric cancer progression, though there is no functional annotation in piRNA databases. The impacts of genetic variants in piRNA genes and their influence in gastric cancer development remains elusive, highlighting the gap in piRNA regulatory mechanisms knowledge. Here, we discuss the current state of understanding of piRNA-mediated regulation and piRNA functions and suggest that genetic alterations in piRNA genes may affect their functionality, thus, it may be associated with gastric carcinogenesis.

In the era of precision medicine, investigations about genetic and epigenetic mechanisms are essential to further comprehend gastric carcinogenesis and the role of piRNAs as potential biomarkers for translational research.

Open Access PDF

Concepts Keywords
Biomarkers Transposon silencing
Cancer RNA interference
Carcinogenesis Carcinogenesis
Carcinogenic Transposable element
Deregulation Biomarker
Epigenetic Piwi-interacting RNA
Genetic Epigenetics
PiRNA Branches of biology
Precision Medicine Carcinogenesis
Regulatory RNAs Cancer
Transposable Elements


Type Source Name
drug DRUGBANK L-Lysine
disease MESH repression
disease MESH risk factors
disease MESH diagnosis
disease MESH adenocarcinomas
drug DRUGBANK Coenzyme M
disease MESH carcinogenesis
disease MESH development
disease MESH cancer
pathway KEGG Gastric cancer
disease MESH Gastric Cancer
pathway KEGG Apoptosis
drug DRUGBANK Melatonin
disease MESH sterility
drug DRUGBANK (S)-4-Nitrostyrene oxide
disease MESH oxidative stress
disease MESH metastasis
disease MESH carcinoma
disease MESH cervical cancer
disease MESH mesothelioma
disease MESH lung cancer
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH glioma
pathway KEGG Glioma
disease MESH melanoma
pathway KEGG Melanoma
disease MESH death
drug DRUGBANK Nonoxynol-9
disease MESH colorectal cancers
disease MESH recurrence
drug DRUGBANK Efavirenz
drug DRUGBANK Troleandomycin
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Thymidine monophosphate
disease MESH insertion mutations
disease MESH B cell Leukemia


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *